{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:20:44Z","timestamp":1785795644980,"version":"3.56.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":2012,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical","doi-asserted-by":"publisher","award":["20141519"],"award-info":[{"award-number":["20141519"]}],"id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical","doi-asserted-by":"publisher","award":["20141519"],"award-info":[{"award-number":["20141519"]}],"id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hyponatremia is associated with poorer outcomes and diuretic response in patients hospitalized for heart failure. This study compared a tolvaptan-based vs. furosemide-based diuretic regimen on short-term clinical responses in hyponatremic acute heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Prospective, randomized, open-label, parallel-group, single-centre study comparing oral tolvaptan vs. continuous infusion furosemide. Thirty-three subjects requiring hospitalization for acute congestive heart failure, and a serum sodium &amp;lt; 135 mmol\/L, were randomized to tolvaptan 30 mg orally daily or furosemide 5 mg\/h intravenously for initial 24 h, after which treatments could be escalated. Median daily dose throughout was tolvaptan 30 mg and furosemide 120 mg, with four subjects in each group requiring dose escalation. Urine output and net fluid balance were not different between groups at 24 h or subsequent time points up to 96 h. Changes in estimated glomerular filtration rate were comparable. Cystatin C improved at 24 h with tolvaptan compared with furosemide (\u22126.4 \u00b1 11.8 vs. 4.1 \u00b1 17.2% change, P = 0.036), but the effect was transient. No significant between group differences were seen for NT-proBNP, plasma renin activity, or urinary neutrophil gelatinase-associated lipocalin:Cr. Serum sodium, as well as copeptin levels, increased with tolvaptan compared with furosemide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oral tolvaptan was associated with similar, but not superior, diuresis compared with intravenous furosemide for acute heart failure with concomitant hyponatremia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12783","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T05:05:55Z","timestamp":1592283955000},"page":"1927-1934","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tolvaptan vs. Furosemide-Based Diuretic Regimens in Patients Hospitalized for Heart Failure with Hyponatremia (AQUA-AHF)"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2251-8268","authenticated-orcid":false,"given":"Tien M.H.","family":"Ng*","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanda P.","family":"Grazette","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Fong","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]},{"name":"MemorialCare Heart & Vascular Institute, University of California-Irvine , Long Beach, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Lou","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani Y.","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Han","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilkumar","family":"Mehra","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Elkayam","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"2026012115032788400_ehf212783-bib-0001","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/qjmed\/hcl120","article-title":"Hyponatraemia as a risk factor for hospital mortality","volume":"99","author":"Asadollahi","year":"2006","journal-title":"QJM"},{"key":"2026012115032788400_ehf212783-bib-0002","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.amjmed.2009.01.027","article-title":"Mortality after hospitalization with mild, moderate, and severe hyponatremia","volume":"122","author":"Waikar","year":"2009","journal-title":"Am J Med"},{"key":"2026012115032788400_ehf212783-bib-0003","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archinternmed.2009.513","article-title":"Impact of hospital-associated hyponatremia on selected outcomes","volume":"170","author":"Wald","year":"2010","journal-title":"Arch Intern Med"},{"key":"2026012115032788400_ehf212783-bib-0004","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1185\/03007990802081675","article-title":"Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients","volume":"24","author":"Zilberberg","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2026012115032788400_ehf212783-bib-0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2265.2006.02583.x","article-title":"Characteristics and mortality of severe hyponatraemia\u2014a hospital-based study","volume":"65","author":"Gill","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026012115032788400_ehf212783-bib-0006","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","article-title":"Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study","volume":"111","author":"Klein","year":"2005","journal-title":"Circulation"},{"key":"2026012115032788400_ehf212783-bib-0007","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade","year":"2007","journal-title":"Eur Heart J"},{"key":"2026012115032788400_ehf212783-bib-0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/17482940701210179","article-title":"Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial","volume":"9","author":"Rossi","year":"2007","journal-title":"Acute Card Care"},{"key":"2026012115032788400_ehf212783-bib-0009","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/archinte.167.18.1998","article-title":"Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial","volume":"167","author":"Gheorghiade","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026012115032788400_ehf212783-bib-0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjcard.2008.09.091","article-title":"Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction","volume":"103","author":"Rusinaru","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026012115032788400_ehf212783-bib-0011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000360604","article-title":"Association of hyponatremia to diuretic response and incidence of increased serum creatinine levels in hospitalized patients with acute decompensated heart failure","volume":"128","author":"Ng","year":"2014","journal-title":"Cardiology"},{"key":"2026012115032788400_ehf212783-bib-0012","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026012115032788400_ehf212783-bib-0013","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"2026012115032788400_ehf212783-bib-0014","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"J Card Fail"},{"key":"2026012115032788400_ehf212783-bib-0015","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"2026012115032788400_ehf212783-bib-0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/1074248412446194","article-title":"Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety","volume":"17","author":"Ng","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012115032788400_ehf212783-bib-0017","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012115032788400_ehf212783-bib-0018","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2215\/CJN.04010907","article-title":"Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study","volume":"3","author":"Bennett","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012115032788400_ehf212783-bib-0019","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00467-011-2075-7","article-title":"NGAL distinguishes steroid sensitivity in idiopathic nephrotic syndrome","volume":"27","author":"Bennett","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2026012115032788400_ehf212783-bib-0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ndt\/gfv457","article-title":"Urinary biomarker incorporation into the renal angina index early in intensive care unit admission optimizes acute kidney injury prediction in critically ill children: a prospective cohort study","volume":"31","author":"Menon","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2026012115032788400_ehf212783-bib-0021","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"2026012115032788400_ehf212783-bib-0022","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012115032788400_ehf212783-bib-0023","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012115032788400_ehf212783-bib-0024","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","article-title":"Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012115032788400_ehf212783-bib-0025","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012115032788400_ehf212783-bib-0026","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012115032788400_ehf212783-bib-0027","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"2026012115032788400_ehf212783-bib-0028","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"2026012115032788400_ehf212783-bib-0029","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2016.11.032","article-title":"Future study with tolvaptan in acute heart failure","volume":"69","author":"Goldsmith","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12783","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/4\/1927\/65901833\/eschf_7_4_1927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/4\/1927\/65901833\/eschf_7_4_1927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:04:08Z","timestamp":1769025848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/4\/1927\/8372690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,6,16]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12783","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"2020-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}